13/06/2019 10:00:00

Maru/Matchbox Appoints Industry Veteran, Peter Jenkins, as Chief Client Officer, UK

SOUTHAMPTON, United Kingdom, June 13, 2019 (GLOBE NEWSWIRE) -- Maru/Matchbox, a sector-focused global insight partner, is pleased to announce the appointment of Peter Jenkins as Chief Client Officer, UK. Peter is based in the firm’s Southampton office.

“After an extensive search I could not be happier that Peter has agreed to join us at this exciting stage in our journey,” said Gary Topiol, CEO, Maru/Matchbox, UK. “Peter will be an integral part of our leadership team as we continue to disrupt the industry. Peter’s broad research experience and compelling customer focus will enable us to build on our reputation for client centricity,” added Topiol.

Peter has over 25 years of demonstrated revenue and capability growth in the market research and insights industry. He has held a number of leadership positions, most recently as Head of Consumer at GfK. The appointment of Peter is a key step in delivery against the Maru/Matchbox strategy: to add value for our clients, continuously leading the way in delivering research, insight and advisory services powered by cutting-edge technology and innovation.

“Peter is a driven, inspirational insights leader with a track record in developing clients, building and leading teams, formulating strategy, creating new solutions and driving profitable growth,” said Maru Group CEO, Ged Parton. “I’m very excited to have him join the team,” he added.

Peter will be responsible for overseeing client relationships and ensuring their satisfaction across Maru/Matchbox UK, defining and managing best practice with clients across the business, and managing the company’s sector focused client services teams.

About Maru/Matchbox

Maru/Matchbox

began disrupting the market research industry in 2000. We’re a different breed of global insight partner, built on proprietary technology that enables our experts to connect with the people that matter most to our clients. Our people bring deep sector-focused knowledge to client projects, so they can build and maintain a competitive advantage. We have agile tech platforms to connect with customers, provide on-demand insight and combine quality research and analytics data sources. We exist to help great organisations spark better connections.

Contact: media@marumatchbox.com

maru-matchbox-logo-blue-gold.png

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
20 Jun
 
I øjeblikket sidder "vinderne" ved folketingsvalget og forhandler regeringsgrundlag. De er enige om ..
44
18 Jun
 
Ingen grund til at flytte, de fleste har ikke råd, det er altid middelklassen det rammer og alligeve..
34
20 Jun
 
Måske jeg er den eneste, men savner Alpehue og hans gode indlæg... er han her under et andet alias? ..
23
23 Jun
 
Kære Nets-formand, du er i Danmark, ikke USA Vi er et samfund, hvor få har for meget og færre for li..
20
21 Jun
VELO
Mangel på to tacrolimus - konvertere pat. til Envarsus   I USA konvertere de patienter til Envarsus ..
20
21 Jun
 
@ckt - synes egentlig det havde vaeret bedre, du ikke havde skrevet noget overhovedet..
20
19 Jun
OMXC25
  De vil aldrig få penge nok. Jeg vil tro, at der aldrig er tilført de offentlige kasser flere penge..
20
20 Jun
CHEMM
ChemoMetec opjusterer forventningerne til omsætningen og driftsresultatet som følger af højere forve..
19
21 Jun
VELO
Ser ud til at man omkring 1 juli starter et nyt forsøg op med Envarsus hvor man tilsyneladende forve..
17
18 Jun
AMBU-B
Jeg er rigtig tilfred med de udmeldinger JJG kommer med idag. Det giver ro over deres udmeldinger, o..
17

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
OSE Immunotherapeutics Will Participate in HealthTech Investor Days (HTID)
2
Global Arena Holding Inc. (GAHC), Files First Quarter 10Q, and Updates Shareholders on Subsidiaries
3
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Eros International Plc (NYSE: EROS) and Encourages Eros Investors to Contact the Firm
4
Hofseth Biocare ASA: Signed Letter of Intent with Garden of Life® for exclusive use of CollaGo® and ProGo® in the US market
5
Final Data Analysis of Phase 2 PBC Trial Shows that Genkyotex’s Anti-fibrotic Candidate GKT831 Demonstrated Statistically Significant Improvements in GGT and ALP Over Full Treatment Period

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
24 June 2019 23:36:24
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190527.1 - EUROWEB7 - 2019-06-25 00:36:24 - 2019-06-24 23:36:24 - 1000 - Website: OKAY